Anti-tumor effect of bevacizumab on a xenograft model of feline mammary carcinoma

Access this Article

Author(s)

    • OHTSUKA Aya OHTSUKA Aya
    • Department of Veterinary Pathology, Nippon Veterinary and Life Science University, 1–7–1 Kyonan-cho, Musashino, Tokyo 180–8602, Japan
    • NAKAHIRA Rei NAKAHIRA Rei
    • Department of Veterinary Pathology, Nippon Veterinary and Life Science University, 1–7–1 Kyonan-cho, Musashino, Tokyo 180–8602, Japan
    • TAJIMA Tsuyoshi TAJIMA Tsuyoshi
    • Department of Veterinary Pharmacology, Nippon Veterinary and Life Science University, 1–7–1 Kyonan-cho, Musashino, Tokyo 180–8602, Japan
    • SASAKI Nobuo SASAKI Nobuo
    • Department of Veterinary Surgery, The University of Tokyo, 1–1–1 Yayoi, Bunkyo, Tokyo 113–8657, Japan
    • ARAI Toshiro ARAI Toshiro
    • Department of Veterinary Biochemistry, Nippon Veterinary and Life Science University, 1–7–1 Kyonan-cho, Musashino, Tokyo 180–8602, Japan

Abstract

Feline mammary carcinomas are characterized by rapid progression and metastases. Vascular endothelial growth factor (VEGF) is a key regulator of tumor angiogenesis, proliferation and metastasis. The present study aimed to investigate the effects of a single drug therapy of bevacizumab on a xenograft model of feline mammary carcinoma expressing VEGF protein. Bevacizumab treatment suppressed tumor growth by inhibiting angiogenesis and enhancing apoptosis; however, it did not affect the tumor proliferation index. Thus, bevacizumab had anti-tumor effects on a xenograft model, and this may be useful for the treatment of feline mammary carcinoma.

Journal

  • Journal of Veterinary Medical Science

    Journal of Veterinary Medical Science 78(4), 685-689, 2016

    JAPANESE SOCIETY OF VETERINARY SCIENCE

Codes

  • NII Article ID (NAID)
    130007331507
  • NII NACSIS-CAT ID (NCID)
    AA10796138
  • Text Lang
    ENG
  • ISSN
    0916-7250
  • NDL Article ID
    027341681
  • NDL Call No.
    Z18-350
  • Data Source
    NDL  J-STAGE 
Page Top